EPS for DiaMedica Therapeutics Inc. (DMA) Expected At $-0.01

April 16, 2018 - By Ellis Scott

DiaMedica Therapeutics Inc. (CVE:DMA) Logo

Analysts expect DiaMedica Therapeutics Inc. (CVE:DMA) to report $-0.01 EPS on April, 26.After having $-0.01 EPS previously, DiaMedica Therapeutics Inc.’s analysts see 0.00 % EPS growth. The stock increased 5.45% or $0.03 during the last trading session, reaching $0.58. About 129,600 shares traded. DiaMedica Therapeutics Inc. (CVE:DMA) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of novel recombinant proteins and monoclonal antibodies. The company has market cap of $98.52 million. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein with a focus on acute vascular diseases, such as acute ischemic stroke and kidney injury indications. It currently has negative earnings. It also develops DMDx, a companion diagnostic in vitro assay for kidney diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.